"earnings call"? LOL.
We are a drug development company in the early stages of introducing a novel product that has high potential but also significant marketing costs; and as a novel product, we can expect a long runway to achieving its full sales potential - and that's just in Singapore. So you will need to evaluate the future prospects of our company somewhat qualitatively and not based on EPS - at least for the time being. FYI, our 4C at 30 September reported sales of $17k. I'm sure they will improve in the December quarter with the HCP marketing starting in Singapore, but let's not set ourselves up for disappointment by expecting profits, just yet.
"earnings call"? LOL.We are a drug development company in the...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.16M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 85427 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 17195 | 2 |
View Market Depth
| Last trade - 07.06am 17/06/2025 (20 minute delay) ? |
| FRE (ASX) Chart |
Day chart unavailable